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Introduction: Cinnamon is currently marketed as a remedy for obesity, glucose intolerance, diabetes mellitus and
dyslipidaemia. Integrative medicine is a new concept that combines conventional treatment with evidence-based
complementary therapies.
Aim: The aim of this review is to critically evaluate the experimental evidence available for cinnamon in improving
glycaemic targets in animal models and humans.
Results: Insulin receptor auto-phosphorlylation and de-phosphorylation, glucose transporter 4 (GLUT-4 ) receptor
synthesis and translocation, modulation of hepatic glucose metabolism through changes in Pyruvate kinase (PK)
and Phosphenol Pyruvate Carboxikinase (PEPCK), altering the expression of PPAR (γ) and inhibition of intestinal
glucosidases are some of the mechanisms responsible for improving glycaemic control with cinnamon therapy.
We reviewed 8 clinical trials that used Cinnamomum cassia in aqueous or powder form in doses ranging from
500 mg to 6 g per day for a duration lasting from 40 days to 4 months as well as 2 clinical trials that used
cinnamon on treatment naïve patients with pre-diabetes. An improvement in glycaemic control was seen in
patients who received Cinnamon as the sole therapy for diabetes, those with pre-diabetes (IFG or IGT) and in
those with high pre-treatment HbA1c. In animal models, cinnamon reduced fasting and postprandial plasma
glucose and HbA1c.
Conclusion: Cinnamon has the potential to be a useful add-on therapy in the discipline of integrative medicine
in managing type 2 diabetes. At present the evidence is inconclusive and long-term trials aiming to establish the
efficacy and safety of cinnamon is needed. However, high coumarin content of Cinnamomum cassia is a concern,
but Cinnamomum zeylanicum with its low coumarin content would be a safer alternate.




Cinnamon, which is derived from a Greek word that
means sweet wood, comes from the inner bark of tropical
evergreen cinnamon trees [1]. Cinnamomum (cinnamon) is
a genus of the Lauraceae family, many of whose members
are used as spices [2]. It is one of the most widely used fla-
vouring agents used in the food and beverage industry
worldwide and well recognized for its medicinal properties
since antiquity. Traditional Ayurvedic medicine has used
cinnamon extracts for ailments such as arthritis, diarrhoea
and menstrual irregularities [3].
To date, about 250 species of cinnamon has been
identified, 4 of which are used to obtain the spice cinna-
mon. True or Ceylon Cinnamon (Cinnamomum verum)
(syn C. zeylanicum) is a small evergreen tree native to
Sri Lanka. Chinese cassia cinnamon (Cinnamomum cassia)
is the other most widely available species [4].
Preparation of cinnamon involves stripping of the outer
bark of the tree and letting the inner bark to dry and
curl up into its customary cinnamon quills. Cinnamon
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is available in either its whole quill form (Cinnamon
sticks) or as ground powder in the market [5].
At present Cinnamon is sold as both a preventative
and therapeutic supplement for many ailments including,
metabolic syndrome, insulin resistance, type 2 diabetes,
hyperlipidaemia and arthritis [5].
Cinnamon is known to have anti-diabetic properties, in
addition to which, it is also perceived to have anti-oxidant,
anti-inflammatory and anti-bacterial properties [6, 7].
Burden of diabetes and use of complementary medicines
Increasing prevalence of diabetes mellitus is a major cause
of morbidity and mortality worldwide. The WHO estimates
a prevalence of 347 million people with diabetes worldwide
in 2015 [8]. Diabetes mellitus is an illness, where a wide
array of complementary and alternative medicines (CAMs)
has been used with varying success. Around 2-3.6 million
people in the United States rely on complementary and
alternative medicines for the treatment of their diabetes
mellitus [9].
Studies have been consistent in showing that diabetic
patient adherence to current conventional treatment
protocols are poor [10]. Diabetic patients are 1.6 times
more likely than non-diabetics to use a CAM for a host of
reasons [11].
Complex treatment regimes, hypoglycaemia, patient
beliefs and side effects of medications have been com-
pelling reasons that limited patient compliance with
conventional treatment [9].
The worldwide trend for the use of CAMs in diabetes
has increased with an overall prevalence ranging between
30-57 % [12].
Recent estimates show that over 80 % of people living
in developing countries depend on CAM for treatment
of health conditions [9]. In the United States an increase
of 380 % is seen in the use of herbal remedies [13]. The
economic burden of CAMs is substantial, with the UK
population in 2001 having spent an estimated 340 million
pounds on CAMs [14]. More recently in 2013, Herman
estimates the cost of Complementary and Integrative
Medicine (CIM) in the US to be 34 billion dollars [15].
Integrative medicine is a new discipline of medicine
that combines conventional medicine with evidence-based
complementary medicines. Patients with diabetes are in-
creasingly eager to be part of their disease management
and keen to try out integrative strategies that involve life-
style changes and self management [16].
Therefore it is timely to review the evidence that supports
its use at both molecular and clinical levels.
Pathogenesis of Type 2 diabetes and insulin resistance
Type 2 diabetes is a complex metabolic disorder of insulin
sensitivity and action on peripheral tissues like skeletal
muscle and adipose tissue and of impaired insulin
secretion.
Insulin signaling involves a cascade of events initiated
by insulin binding to its cell surface receptor. The receptor
consists of 2 α and 2 β subunits that is disulfide linked into
a hetero-tetrameric complex. Insulin binds to the extracel-
lular α subunits, activating the intra cellular tyrosine kin-
ase domain of the β subunit. This is followed by receptor
autophosphorylation, and activation of receptor tyrosine
kinases, which result in tyrosine phosphorylation of insu-
lin receptor substrates (IRSs) including IRS1, IRS2, IRS3,
IRS4, Gab1, and Shc [17].
The β subunit is known to undergo serine/threonine
phosphorylation, which decreases its ability to autopho-
sphorylate to initiate the phosphorylation of the IRSs in
insulin resistant animal models and humans. The activa-
tion of AMP activated protein kinase (AMPK) induces the
translocation of glucose transporter 4 (GLUT4) to the
plasma membrane [18], and several studies have demon-
strated that AMPK and its signaling pathway are potential
molecular targets in the development of drugs for the
treatment of type 2 diabetes and obesity [19].
IRSs also leads to translocation of insulin mediated
GLUT-4 from intracellular vesicles to the plasma mem-
brane, facilitating glucose entry. In the same process, the
insulin receptor is dephosphorylated and inactivated.
This internalization and the dephosphorylation of the insu-
lin receptor are done by the protein tyrosine phosphatases.
Therefore the physiological action of insulin is a delicate
balance between phosphorylation and dephsophorylation.
Phosphatidylinositol 3-kinase (PI3K) is a key component
of the insulin-signaling cascade, essential for the meta-
bolic effects of insulin on glucose transport and GLUT4
translocation [17].
Derangement of insulin signaling pathways such as the
impaired activation of the phosphatidylinositol 3-kinase
and downstream signaling is thought to be responsible
for the onset of insulin resistance and diabetes.
Chemical composition, active constituents and
metabolism
A plant is made up of many thousands of bioactive com-
pounds and isolation of such compounds can be tedious
and time consuming.
Jayaprakasha et al in 2011, using hydro-distillation
techniques attempted to isolate the volatile oils of Cinna-
mon contained in the leaves and the bark. The major
compounds were found to be Eugenol, cinnamaldehyde,
copane, cinnamyl acetate and camphor, along with minor
constituents [4]. Previous investigators had isolated Cinna-
maldehyde, cinnamyl acetate and camphor from the bark.
The active compound of Cinnamon with hypoglycaemic
activity is a contentious issue [20]. To date, multiple com-
pounds with hypoglycaemic properties have been isolated
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and used in both animal and clinical trials. A few such
compounds are briefly discussed.
Babu et al used cinnamaldehyde extracted from Cinna-
momum zeylanicum to demonstrate a significant reduction
of plasma glucose and HbA1c levels in streptozotcin
induced diabetic rats [21]. This study was carried out
to isolate and identify the putative anti-diabetic compounds
based on bioassay-guided fractionation. Cinnamaldehyde
thus isolated was orally fed to diabetic rats, which caused
significant reduction of plasma glucose and increased insu-
lin levels. The authors concluded that cinnamaldehyde is
responsible for increasing insulin secretion from pancreatic
β cells and thus ameliorating glucose levels [21].
The stem of cinnamomum cassia (Cinnamoni ramulus)
has been used in rats to determine its pharmacokinetic
properties. The essential oil of cinnamoni ramulus is made
up of a large number of aromatic compounds, which
include cinnamaldehyde, cinnamic acid and 2-methoxy
cinnamic acid. Bin Ji and colleagues demonstrated that
following the oral administration of 15 mg cinnamon
oil, the Cmax and the AUC for 2-methoxy cinnamic acid
(0.01 % in essential oil of cinnamon ramulus) were
greater than those of cinnamaldehyde (83.49 % in essential
oil of cinnamoni ramulus) implying that the active metab-
olite of the essential oil might be 2-methoxy cinnamic acid
[22]. Chen demonstrated that the bioavailability of cin-
namic acid was higher when cinnamoni ramulus was fed
to rats in contrast to when pure cinnamic acid was fed.
Pure cinnamic acid was quickly transformed into hippuric
acid. Cinnamldehyde in the cinnamoni ramulus is metabo-
lized into cinnamic acid in the liver [23].
In another study, Anderson et al demonstrated the ac-
tive ingredient responsible for the anti-diabetic effect of
Cinnamon is probably a water soluble constituent. In this
study, specimens from C. cassia, C. verum, C, burmanni
and C. loureinii were tested. Insulin enhancing biological
activity of cinnamon was measured using epididymal fat
cell assay. Adipocytes and glucose were incubated in the
presence of insulin and or insulin and aqueous extract of
cinnamon.
Water-soluble polyphenol polymers from cinnamon, that
increase insulin-dependent in vitro glucose metabolism
roughly 20-fold and display antioxidant activity were
isolated by them and was characterized by nuclear mag-
netic resonance and mass spectroscopy. The polymers were
composed of monomeric units with a molecular mass of
288 [24]. These compounds have been identified as trimers
and tetramers of the flavonoids, catechin and epicatechin.
These cinnamon polyphenols (CP) with doubly linked pro-
cyanidin type-A polymers appear to be unique for their
insulin-like activity, because other cinnamon compounds
display little or no such activity [24].
The other compounds of cinnamon that showed little or
no insulin like activity included; cinnamic acid, cinnamide,
cinnamyl alcohol, eugenol and 2-methoxy-cinnamaldehyde
under the assay conditions of this study. There was no
difference in the insulin like activity between the different
species tested.
The available evidence regarding the active compound(s)
of cinnamon remains inconclusive. Multiple active com-
pounds at different levels in the insulin signaling pathway is
probably a safe intermediary interpretation until more
robust evidence emerge.
Potential mechanisms of action
The mechanism by which cinnamon exerts its anti-diabetic
activity is debated and is probably the result of its action at
different levels of the insulin-signaling pathway.
Insulin receptor
The cellular response to insulin is mediated through the
insulin receptor, which is a tetrameric protein consisting
of two identical extracellular α-subunits that bind insulin
as well as two identical transmembrane β-subunits that
have intracellular tyrosine kinase activity [25]. When insulin
binds to the α-subunit of the receptor, the β-subunit tyro-
sine kinase is activated, resulting in autophosphorylation of
β-subunit tyrosine residues [26].
Increased autophosphorlylation and decreased dephos-
phorylation [27] of the insulin receptor is one mechanism
that increases the insulin sensitivity. Cinnamtannin B1, a
proanthocyanidin isolated from the stem bark of Ceylon
cinnamon, activates the phosphorylation of the insulin
receptor β-subunit on adipocytes as well as other insulin
receptors [28].
Glucose transporter 4 (GLUT 4)
GLUT4 is the major glucose transporter in skeletal muscle
and adipose tissue, which is under control of insulin. It is
well established that insulin promotes the translocation of
GLUT-4 from the intracellular compartment to the cell
membrane [29]. In diabetes mellitus because of the ab-
sence or insufficient sensitivity to insulin, GLUT 4, is
decreased. Nikzamir and colleagues reported a significant
increase in the expression of GLUT 4 receptor and its
mRNA, in cinnamaldehyde treated C2C12 skeletal muscle
cells using Real Time PCR [30].
Recently Shen et al reported that cinnamon extract
ameliorates type 2 diabetes by inducing GLUT4 trans-
location via the AMPK signaling pathway. The activation
of AMPK induces the translocation of GLUT4 to the
plasma membrane, and several studies have demonstrated
that AMPK and its signaling pathway are potential
molecular targets in the development of drugs for the
treatment of type 2 diabetes and obesity [19].
Cinnamon increases the amount of GLUT4 receptors
as well as Insulin Receptor (IR) and Insulin Receptor
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substrates [19, 31, 32], thereby facilitating glucose entry
into cells.
Shen et al demonstrated that extracts of Cinnamomum
zeylanicum increased the production and translocation
to the plasma membrane of the GLUT 4 in brown adipose
tissue and muscle in a dose dependent manner [33]. Anand
et al demonstrated a similar finding but quantified the ef-
fect by demonstrating an increase of the membrane trans-
location of GLUT4 from 42.8 % to 73.1 % in cinnamon
treated rats when compared to healthy controls [34].
Glucose transporter-1 (GLUT 1)
Glucose transporter-1 (GLUT-1) is a receptor expressed
on mammalian cells that is responsible for basal glucose
uptake into cells. The exact mechanism of activation of
this receptor is poorly understood [35]. L 929 fibroblasts
are totally dependent on GLUT-1 receptors for glucose
uptake into cells [36]. Plaisier and colleagues demonstrated
cinnamldehyde increases the GLUT 1 mediated glucose up-
take in a dose dependent manner in the L 929 fibroblasts.
However in the presence of glucose deprivation in the
medium, cinnamldehyde reduced the GLUT 1 mediated
glucose uptake [37].
Glucagon-like peptide-1 (GLP-1)
Plexopathy demonstrated a dose dependent reduction of
serum insulin concentrations and an increase in glucagon-
like peptide 1(GLP-1) with cinnamon treatment [38]. Simi-
larly Hlebowicz et al in 2009 reported that the addition of
3 g of cinnamon to a rice meal caused significant increase
of GLP-1 levels with decreased serum insulin [39]. Im-
proved glucose transport across the cell membrane reduces
the insulin resistance and this probably accounts for
the reduced insulin levels.
Peroxisome proliferator activator receptor (PPAR)
Peroxisome proliferator-activated receptor gamma (PPAR-γ
or PPARG), is a type II nuclear receptor that, in humans is
encoded by the PPARG gene. This gene encodes a member
of the peroxisome proliferator-activated receptor (PPAR)
subfamily of nuclear receptors [40]. PPARs form het-
erodimers with retinoid X receptors (RXRs) and these
heterodimers regulate transcription of various genes.
Three subtypes of PPARs are known: PPAR-α, PPAR-δ,
and PPAR-γ. The protein encoded by this gene is PPAR-γ
and is a regulator of adipocyte differentiation. Activation
of PPAR lowers plasma triglycerides and elevates plasma
HDL cholesterol levels [41], at the same time increasing
insulin sensitivity leading to its anti-diabetic effects [42].
PPAR agonists such as Pioglitazone are currently being
used as potent anti-diabetic agents in conventional
medicine [43].
Cinnamon causes an increase in the expression of PPAR
(α) and PPAR (γ), thereby increasing insulin sensitivity [44].
Sheng et al demonstrated that the water-soluble extract
of Cinnamon has the ability to induce the expression of
PPARα and PPARγ both in vitro and in vivo in mouse
adipose tissue. Further, treatment of mouse 3 T3-L1
pre-adipocytes with cinnamon extracts caused them to
differentiate into adipocytes [44].
α glucosidase activity
Adisakwattana studied the inhibitory effects of 4 types of
cinnamon on intestinal maltase and sucrase, pancreatic
α-amylase, and their combined effect in the presence
with acarbose [45].
The HPLC fingerprints of each cinnamon species were
established. Among cinnamon species, Thai cinnamon
extract was the most potent inhibitor against the intestinal
maltase.
They also demonstrated that Ceylon cinnamon was most
the potent inhibitor of pancreatic amylase and intestinal
sucrase. However its potency to inhibit these 2 enzymes
was less than that of acarbose [45]. However when used
together with acarbose the cinnamon extracts produced
an additive inhibitory effect against all 3 enzymes.
Ranilla et al also demonstrated that Ceylon cinnamon
possessed a high dose dependent inhibition of alpha glu-
cosidase and pancreatic alpha amylase [46].
These results suggest that cinnamon bark extracts may
be potentially useful for the control of postprandial glu-
cose in diabetic patients through inhibition of intestinal
α-glucosidase and pancreatic α-amylase.
Effects on gluconeogenesis
Pyruvate kinase (PK) and Phosphenol Pyruvate Carboxi-
kinase (PEPCK) are 2 key enzymes regulating the hepatic
glucose metabolism. In diabetic rats the PK activity is re-
duced and PEPCK activity is elevated. The reduced PK
activity of Streptozotocin treated rats is restored to near
normal values upon treatment with cinnamon. This ef-
fect is also observed when diabetic animals are treated
with Glibenclamide as well, but the response is less com-
pared to cinnamon [34]. Similarly, significantly elevated
PEPCK activity of Streptozotocin induced diabetic rats
again nearly normalizes albeit at a slightly higher value
than normal values on treatment with cinnamon [34].
The net result is a stimulation of Glycogen synthesis and
inhibition of gluconeogenesis, improving glucose metab-
olism (Fig. 1).
Gastric emptying
Hlebowicz et al studied the effect of cinnamon on Gastric
Emptying Rate (GER) of 14 healthy adults. The GER was
measured by using standardized real-time ultrasonography.
The subjects were examined after an 8-hour fast if they had
normal fasting plasma glucose (FPG) concentrations. The
subjects were given 300 g of rice pudding with or without
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the addition of 6 g of cinnamon. Addition of cinnamon de-
layed the gastric emptying but caused a more pronounced
reduction in post prandial blood glucose and did not affect
satiety [47]. However the addition of either 1 or 3 g of cin-
namon to a rice meal did not have any effect on the GER
or the glucose levels [39].
Efficacy in animal studies
Ranasinghe et al performed a meta-analysis of studies
utilizing Cinnamon zeylanicum. In vivo studies utilizing
diabetic rats were included, and they analyzed the effect
of cinnamon on weight, (FPG), total cholesterol, HDL-
cholesterol, triglycerides and serum insulin. Cinnamon
was able to check the weight loss of diabetic rats. It also
improved the FPG [9].
The result for total cholesterol was conflicting with some
trials showing an increase in cholesterol with cinnamon
[33, 48] while others showed a reduction [49]. HDL-
cholesterol showed an increase with cinnamon treatment
[48, 49]. Triglyceride levels also showed a distinct reduction
in comparison to controls [9].
Anand et al. demonstrated that the HbA1c of diabetic
rats treated with cinnamon and Glibenclamide was less
than that of untreated control diabetic rats [34]. Subash
Babu demonstrated an HbA1C reduction of 40.2 % in
cinnamon treated rats compared to untreated diabetic rats
[49]. However, Ranasinghe et al failed to demonstrate a
significant fall of HbA1c in cinnamon treated diabetic rats
after 30 days treatment, although significant reduction
was observed in fasting and postprandial glucose [50]. The
failure to demonstrate an improvement in HbA1C may be
due to the short duration of 30 days, of this trial.
Kannappan et al. [51] demonstrated the ability of cin-
namon to reduce the blood glucose of high fructose diet
Fig. 1 Molecular mechanisms of Cinnamon by which it exerts hypoglycaemic activity. PK: Pyruvate Kinase, PEPCK: Phosphoenol Carboxy Kinase,
PPAR-gamma: Peroxisome Proloferator Activated-Receptor gamma, WAT: White Adipose Tissue, ACO: Acyl-CoA Oxidase, GLUT-4: Glucose transporting
protein 4, LPL: Lipoprotein lipase, CD36:Fatty Acid Transporter
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fed rats. The mean FPG of high-fructose fed rats was
high compared to control rats. Treatment with cinnamon
caused significant decrease of FPG in the high-fructose fed
rats compared to high fructose fed untreated rats. The
high fructose fed rats had high serum insulin levels and
HbA1c. Upon treatment with cinnamon there was sig-
nificant decrease of both serum insulin and HbA1c.
Additionally the elevated total plasma cholesterol, tri-
glycerides and free fatty acids in the high fructose fed
rats normalized following administration of cinnamon.
Shihabudeen et al. studied the effect of cinnamon on
post-prandial blood glucose of maltose and sucrose loaded
Streptozotocin induced diabetic rats. Cinnamon caused a
65.1 % reduction in the glycaemic response of normal rats
following maltose loading. In diabetic rats compared to
controls, there was a 78.2 %, 86.3 % and 54.2 % reduction
in the glycaemic response when treated with escalating
doses of cinnamon of 300 mg/kg, 600 mg/Kg and 5 mg/
Kg of Acarbose respectively. There was a similar response
with sucrose loading. However the study failed to show a
reduction in glycaemic response in glucose treated healthy
and diabetic rats treated with cinnamon [52].
Shalaby et al. studied the effect of cinnamon on al-
loxan induced obese diabetic Sprague Dawley rats. The
test animals were initially fed a high fat diet and then
injected with alloxan to make them diabetic. Cinnamon
administration caused significant reductions in weight,
glucose, and lipid levels and normalized elevated liver
enzymes while increasing the insulin levels [53].
Efficacy in human studies
To date, several randomized controlled studies exist that
studied the effect of cinnamon on type 2 adult diabetic
patients. These studies variably studied the effect of cin-
namon on glycosylated haemoglobin, FPG, total choles-
terol, LDL cholesterol and triglycerides [54–61].
Seven trials used Cinnamomum Cassia, Cinnamomum
aromaticum or cinnamomum burmanii. 1 trial did not
specify the type of cinnamon used [57]. None of the trails
used Cinnamomum zeylanicum.
The duration of these interventions ranged from 40 days
to 4 months, the patient numbers varied from 25 to 137 in
each trial and the amount of cinnamon administered per
day varied from 500 mg to 6 g.
Of these studies, 2 showed no significant reduction in
glucose values [55, 56], while 5 others showed reduc-
tions in FPG levels and or glycosylated haemoglobin
[54, 57–60].
Khan et al. in 2003 studied a total of 60 patients, who
were randomized to receive 1,3, or 6 g of cinnamon daily
or a placebo. The background medication consisted of
sulphonyureas only. At the end of 40 days, all 3 doses of
cinnamon caused a significant decrease in FPG (18-
29 %), total cholesterol (12-26 %), triglycerides (23-30 %)
and LDL cholesterol (7-27 %) [58]. The change in HDL
cholesterol was not significant. This study did not evaluate
the effect of the intervention on HbA1c.
Mang et al. randomized 79 type 2 adult diabetes pa-
tients on oral hypoglycaemic treatment or diet to receive
either 3 g of cinnamon aqueous extract per day or placebo,
in a randomized double blind clinical trial of 4 months
duration. The study demonstrated a significant decrease
of 10.3 % of the initial FPG values. However, the trial failed
to demonstrate a significant lowering of HbA1c or plasma
lipids [59]. The decrease in plasma FPG correlated signifi-
cantly with the initial baseline concentrations indicating
that patients with a higher initial glucose may benefit
more from the addition of cinnamon.
Crawford studied the administration of 1 g of cinnamon
as an-add on to usual care of diabetes in 109 type 2 diabetic
patients. Participants were randomly allocated to either
usual care with management changes by their primary care
physician or to usual care with management changes plus
1 g cinnamon capsules daily for 90 days. HbA1c was drawn
at baseline and at 90 days and compared with intention-to-
treat analysis. Patients receiving cinnamon had a significant
reduction of their HbA1c by 0.83 % as opposed to 0.37 %
reduction in patients receiving usual care alone [57].
Akilen et al in a randomized, placebo-controlled double
blind clinical trial studied the effect of Cinnamon on 58,
type 2 adult diabetic patients on oral hypoglycaemics by
administering 2 g of cinnamon or placebo daily over a
period of 12 weeks. The patients had an HbA1c greater
than 7 % at recruitment. The results demonstrated a
significant reduction in the HbA1c from 8.22 % to
7.86 % in the treatment group. The study also demon-
strated a significant reduction in blood pressure, FPG,
body mass index (BMI) and waist circumference at
12 weeks of treatment [60].
Suppapitiporn studied the effect of cinnamon cassia
powder in 60 type 2 diabetic patients on oral therapy
consisting of Metformin or sulphonylurea in a random-
ized, placebo-controlled single blind clinical trial. After a
12-week period, HbA1c had decreased from 8.14 % to
7.76 % in the cinnamon group and from 8.06 % to
7.87 % in the placebo group. However the proportion of
patients achieving HbA1c < or = 7 % was greater in patients
receiving Cinnamon, compared to patients receiving
placebo. Nevertheless, it was not found to be statistically
significant [54].
More recently, Anderson et al in a RCT randomized
137 diabetic individuals to receive a commercial prepar-
ation of cinnamon (CinSulin 500 mg/day) or placebo for
2 months. CinSulin constituted a spray-dried water extract
of cinnamon. The study measured the FPG, 2-hr glucose
and the insulin resistance (using the HOMA-IR). Add-
itional measurements included the systolic and diastolic
blood pressures, serum lipids and fructosamine levels. At
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the end of 2 months the authors demonstrated a sig-
nificant decrease of both FPG (In the cinnamon treated
group; 8.85 ± 0.36 to 8.19 ± 0.29 mmol/L (p < 0.005),
compared with 8.57 ± 0.32 to 8.44 ± 0.34 mmol/L in the
placebo control group (p 1⁄4 0.45), 2-hr glucose values
following 75 g glucose load (in the cinnamon extract-
supplemented group, 15.09 ± 0.57 to 13.3 ± 0.55 mmol/L
(P < 0.001), compared with non-significant differences in
the placebo group, 14.18 ± 0.60 to 13.74 ± 0.58 mmol/L).
Insulin sensitivity, assessed by HOMA-IR, was also signifi-
cantly improved by cinnamon extract as were fructosa-
mine concentrations [20].
Vanschoonbeek et al studied the effect of 1.5 g of cin-
namon per day on insulin sensitivity/glucose tolerance
and blood lipids on 25 Type 2 post-menopausal women
on oral hypoglycaemic medications over a period of
6 weeks in a placebo controlled study. They demon-
strated that cinnamon made no significant improvement
in either blood glucose or lipids at the end of the study
period [55].
Blevins et al studied the effect of 1 g of cinnamon cassia
on blood glucose and lipids in 60 type 2 diabetic subjects
in a placebo-controlled study over a 3-month duration.
The trial did not show a significant improvement in either
blood glucose or lipids at the end of the study [56].
In a systematic review and meta analysis published in
2012, Akilen et al reviewed 6 RCTs (n = 435 patients) that
studied the glycaemic outcomes of cinnamon in type 2
diabetes. The meta analysis of RCTs showed, a significant
decrease in mean HbA1c (0.09 %; 95 % CI was 0.04-0.14)
and FPG (0.84 mmol/L; 95 % CI was 0.66-1.02) [62].
Allen et al performed another systematic review and
meta analysis of 10 RCTs (n = 543 patients) published up
to 2012. They demonstrated that cinnamon significantly
reduced FPG (-24.59 mg/dl; 95 % -40.52 to -8.67 mg/dl),
but not HbA1c levels (-0.16 %; CI -0.39 % to 0.02 %) [63].
A Cochrane review published in 2012 analyzed 10
clinical trials involving 577 patients with either type 1 or
type 2 diabetes. The trials used Cinnamomum cassia at
a mean dose of 2 g per day over a period of 4-16 weeks.
The authors concluded that the effect of cinnamon on
FPG was inconclusive and there was no significant re-
duction of HbA1c or post prandial glucose [64].
Ranasinghe et al performed a systematic review and
meta analysis of 16 studies that specifically utilized Ceylon
cinnamon. However, there were no human trials that
utilized Ceylon cinnamon. In animal studies it caused
significant reductions of FPG and HbA1c [9].
A summary of the clinical trials is given below (Table 1).
Effecacy in pre-diabetes
Roussel et al [65] in a double blind placebo-controlled
study investigated the effect of dried aqueous extract of
cinnamon on oxidative stress markers and the possible
correlation with FPG and plasma insulin levels, in over
weight and obese patients with impaired fasting gly-
caemia over a 12-week period. Twenty-two subjects with
FPG in the range of 100-126 mg/dl were selected, and
were either given a placebo or 500 mg/d of cinnamon
over 12 weeks. In the cinnamon group the impaired fast-
ing glucose levels were significantly reduced (114 ± 2.2
to 102 ± 4.3) at the end of 12 weeks. The reduction in
fasting glucose was more pronounced at 12 weeks com-
pared to 6 weeks of supplementation. Similarly, there
was significant improvement in plasma oxidative stress
markers. However, there was no increase in plasma insu-
lin levels [65].
Similarly, Ziegenfuss in a randomized placebo-controlled
double blind clinical trial studied the effect of “ Cinnulin”
500 mg (500 mg of Cinnulin contains 10 g of whole
cinnamon powder according to the manufacturer) per
day on serum chemistry, body weight, and composition
over a 12-week period on 22 adult subjects with the
metabolic syndrome and pre-diabetes. At the end of
12 weeks, the subjects in the Cinnulin group had significant
decrease of FPG (-8.4 %: from 116 ± 12.8 mg/dl (pre) to
106.5 ± 20.1 mg/dl (post), P < 0.01) compared to subjects in
the placebo group [66].
Safety
Anand et al studied the escalating doses of Cinnamo-
mum zeylanicum (100 mg/Kg, 200 mg/Kg and 400 mg.Kg
respectively), all exceeding therapeutic doses on healthy
Wistar rats. They observed no behavioural changes in
the animals. Alanine aminotransferase, aspartate amino-
transferase, alkaline phosphatase, creatinine and total
bilirubin values remained normal during the length of
the study period [34].
However animals administered 20 times the effective
dose of cinnamon showed a slight, insignificant rise in
SGPT, SGOT and ALP, which normalized after 120 hours
following administration [34]. This dose is comparable
to a human adult dose of 600-2400 mg/Kg.
Subash et al demonstrated that significantly elevated
ALP, SGOT and SGPT in streptozotocin induced diabetic
rats near-normalized following the administration of
Cinnamon [49].
Shen at al studied the effect of cinnamon at variable
doses on the glycaemic effect and renal functions of
Streptozotocin induced diabetic rats. Animals receiving
cinnamon extract in doses exceeding 30 mg/Kg, demon-
strated reduction in creatinine values [33].
However, Al-Logmani and Zari demonstrated a signifi-
cant rise in uric acid and blood urea in streptozotocin
induced diabetic rats when compared to controls [67]
upon administration of cinnamon.
Thus in animals there is no significant toxicity of cinna-
mon on the liver, but the results relating to renal functions
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Table 1 Summary of clinical trials using cinnamon and their outcomes







Post intervention ± SD
1 Khan et al [58] Single-blind RCT 40 days intervention
20 days washout
C.cassia powder 1 g,3 g,6 g Placebo 13.77 ± 1.33 13.97 ± 1.23 _ _
Cinnamon 12.0 ± 1.43 9.1 ± 1.40 _ _
2 Mang et al [72] Double- blind RCT 40 days C.cassia aqueous extract 3 g Placebo 8.66 ± 1.47 8.31 ± 1.62 6.71 ± 0.73 6.68 ± 0.7
Cinnamon 9.26 ± 2.26 8.15 ± 1.65 6.86 ± 1.00 6.83 ± 0.83
3 Suppapitiporn et al [54] Single blind RCT 12 weeks C.cassia powder 1.5 g Placebo _ _ 8.14 7.76
Cinnamon _ _ 8.06 7.87
4 Vanschoonbe et al [55] Double-blind RCT 6 weeks C.cassia powder 1.5 g Placebo 8.28 ± 0.33 8.07 ± 0.36 7.1 ± 0.2 7.2 ± 0.2
Cinnamon 8.37 ± 0.64 7.91 ± 0.71 7.4 ± 0.3 7.5 ± 0.3
5 Blevins et al [56] Double-blind RCT 3 months C.cassia powder 1 g Placebo 8.04 8.02 7.1 7.2
Cinnamon 7.38 6.84 7.2 7.4
6 Crawford [57] Randomized placebo controlled
trial (no blind/open)
90 days C.cassia powder 1 g Placebo _ _ 8.28 ± 1.3 7.91 ± 1.5
Cinnamon _ _ 8.47 ± 1.8 7.64 ± 1.7
7 Akilen et al [60] Double-blind RCT 12 weeks C.cassia powder 2 g Placebo 8.77 ± 2.59 8.74 ± 3.11 8.55 ± 1.82 8.68 ± 1.83
Cinnamon 8.82 ± 3.45 8.04 ± 3.10 8.22 ± 1.16 7.86 ± 1.42
8 Anderson et al [20] Randomized placebo
controlled trial
2 months C.cassia(CinSulin) 500 mg Placebo 8.57 ± 0.32 8.44 ± 0.34 _ _











are controversial, raising the need for more studies to
evaluate its effect on the kidney.
A search of the literature for RCTS using human subjects
did not reveal any reported significant adverse events when
Cinnamomum cassia is used in doses of 500 mg-6 g
per day. However there were four instances where pa-
tients reported rash, hives, nausea and one hypoglycaemic
seizure [64].
Although short-term trials have not demonstrated any
significant adverse outcomes with cinnamon cassia use,
its high coumarin content is a concern during prolonged
use [68]. Coumarins are naturally occurring plant com-
pounds with carcinogenic and hepatotoxic properties
[69]. Cinnamon cassia which was used in all the human
trials, has a higher coumarin content compared to true
cinnamon (Ceylon or Sri Lankan Cinnamon) High Per-
formance liquid Chromatography (HPLC) has been used
to quantitatively analyze the content. Sproll and colleagues
demonstrated the coumarin content of true cinnamon was
undetectable while that of cassia cinnamon ranged from
2880-4820mk/Kg using HPLC [70]. Wang and colleagues
using a validated Ultra Performance Liquid Chromatog-
raphy (UPLC) demonstrated the coumarin content of true
cinnamon is minimal, amounting to only 0.017 g/Kg, while
that of other species of cinnamon varied from 0.31 to
6.97 g/kg [68]. In 1988 the Council of the European
Communities set a maximum limit of 2 mg/kg for couma-
rin in many foods and beverages [68].
This high coumarin content of C. cassia and other spe-
cies has led some agencies to advocate against the regular
use of cassia cinnamon as a supplement in diabetes [71].
On the other hand, the very low content of coumarins
found in Cinnamomum zeylanicum makes it a potentially
useful medication or supplement for long-term use.
Effective preparations and dose
Different clinical trials have used different preparations
of cinnamon. In human subjects, Cinnamomum cassia is
the only species of cinnamon that has been used and true
cinnamon or Cinnamomum zeylanicum has not been
studied.
All the studies discussed utilized a powdered form
of cinnamon except the studies by Mang et al and
Crawford which used an aqueous extract of cinnamon
and a commercially available preparation of cinnamon
respectively [57, 59].
Doses varying from 500 mg to 6 g of cinnamon have
been used in studies. However the full dose range seems
to be effective and the hypoglycaemic effect is not dose
dependent [62].
Discussion
The in-vivo and in-vitro studies discussed had evidence
favoring the ability of cinnamon either in dried powder
or aqueous extract forms to improve cellular glucose
metabolism. Many mechanisms, such as increased au-
tophosphorylation of the insulin receptor, increasing
GLUT-4 receptor sysnthesis and enhancing its membrane
translocation, inhibition of pancreatic and intestinal
amylase and glucosidase and increasing hepatic glycogen
synthesis are probably responsible for this effect.
The studies that described individual mechanisms of
action were either in vitro studies or studies that utilized
small numbers of experimental animals or healthy hu-
man volunteers. The evidence from these studies still
remains weak, as the evidence has often been not repli-
cated and some times remained contradictory. Clinical tri-
als have so far not attempted to link the clinical outcomes
to presumed mechanism of action. While individual ac-
tions of cinnamon are described, the relevance of each
mechanism to clinically significant outcomes remains un-
known. Future studies should focus upon linking clinical
outcomes to mechanistic actions thereby making it more
relevant in a physiological context.
The stretpozotocin induced diabetic rat model has
demonstrated the ability of cinnamon to normalize glu-
cose metabolism, lipid abnormalities and weight changes
associated with diabetes. Most of the trials on animal
studies showed the ability of cinnamon to reduce FPG,
postprandial glucose and or HbA1c [34, 49, 52]. Cinna-
mon did not seem to reduce plasma glucose of normal
rats compared to diabetic rats [50]. In animal models fed
high fructose diets the hyperinsilinaemia, FPG, elevated
total cholesterol and triglycerides normalized following
treatment with cinnamon [51]. This effectively demon-
strates the normalization of the biochemical parameters
of an insulin resistant animal model.
However, the clinical trials have proven more difficult
to interpret and the results have been more heterogeneous
and conflicting.
All studies discussed, had patients with widely varying
baseline characteristics such as age, gender and duration
since diagnosis; and direct comparison and generalizations
may not be valid between studies. There may have been
other confounders such as social habits, ethnicity and
dietary substances that influenced the action of cinnamon.
Although the active ingredient responsible for glucose
lowering has not been characterized with certainty, studies
have shown that the concentrations cinnamaldehyde vary
between species and even among formulations [72].
Consequently it would be difficult to achieve predictable
results in clinical trials. Additionally variations in the
manufacturing process also affect the quality and availabil-
ity of the active compound, as these complementary prod-
ucts manufacture is not governed to the same exacting
standards of conventional pharmacological products.
Akilen et al and Crawford [57, 60] demonstrated sig-
nificant reductions in HbA1c with cinnamon use. The
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baseline HbA1c values for the Crawford and Akilen
studies were 8.28 % and 8.55 % respectively. However
the Crawford study utilized off the shelf cinnamon cap-
sules from varied sources and the purity and content of
cinnamon is not known. A placebo group was not present
in this study and the results were compared against a
group of patients receiving standard care.
It is interesting to note that the trials that failed to
demonstrate a significant decline in HbA1c had a mean
baseline HbA1c value close to 7 %. (range of 6.8 % to
7.1 %) [55, 56].
Perhaps a valid explanation for these results would be
that the effect of cinnamon is minimal when glucose
control is closer to normal and that it exerts a significant
effect in reducing glucose as the values increase.
Similarly Khan et al [58] in their study which lasted
only 40 days, demonstrated a significant reduction in
FPG. The HbA1c was not measured in this study. The
baseline FPG was 13 mmol/l and 12 mmol/l in the pla-
cebo and treatment groups respectively and the study
demonstrated the ability of cinnamon to reduce glucose
in the presence of higher baseline values.
However, in contrast, when the effect of cinnamon
was studied in patients with impaired fasting glucose, 2
contrasting doses of 10 g and 500 mg of cinnamon per
day respectively was able to reduce the FPG significantly
[65, 66]. In both these studies, Cinnamon was used as
the sole agent that had an impact on blood glucose, in
contrast to the RCTS which used cinnamon as an add-
on therapy to background hypoglycaemic medications.
The background therapy in these studies included oral
hypoglycaemic agents prescribed as monotherapy or a
combination of medications. This raises the possibility
that the glucose lowering potential of cinnamon may
have been masked in the RCTS when it was used in con-
junction with more potent medications as opposed to
being used alone.
The negative outcome of the trial performed by
Vanschoonbeek [55] may be attributable to the short
duration of 6 weeks, which may have given rise to a
false negative HbA1C result. As the life span of red cells is
around 120 days, duration of 2-3 months is required to
demonstrate a change in HbA1c levels.
A recent Cochrane meta-analysis found that Cinna-
mon Cassia used in 8 RCTs in 338 patients did not sig-
nificantly lower the FPG. Similarly there was no
significant reduction in HbA1c, in 6 RCTs that studied
the effect of Cinnamon on 405, type 2 adult diabetic pa-
tients [64].
Hlebowicz demonstrated the potential of cinnamon to
delay gastric emptying and concluded that the fall in
postprandial plasma glucose in subjects who received
cinnamon was disproportionate to the delay induced in
gastric emptying [47]. This raises the possibility of a dual
mechanism in managing the postprandial glucose surge
of diabetic patients; namely the delayed gastric emptying
and the inhibition of pancreatic α-amylase and intestinal
α-glucosidase.
The safety of long-term supplementation using Cinna-
mon cassia has been highlighted recently due to its high
coumarin content [68]. However, Cinnamomum zeylani-
cum, which only contains trace amounts of coumarins, has
not been used in clinical trials. If this form of cinnamon is
found to be an effective agent in lowering plasma glucose,
the low toxicity figures make it an ideal supplement for
long-term use.
Both animal and clinical trials published so far have
studied the effect of cinnamon for short durations only.
In the clinical trials the maximum length of exposure
was recorded by Mang, which lasted for 4 months. Al-
though the adverse events recorded in these studies are
minimal, these need to be recorded over longer periods
of time with a larger population base.
Some clinical trials have used large doses of cinnamon
(6-10 g/day) and the long-term outcomes of such mea-
sures need to be studied.
From a safety point of view, there is the potential to
use true cinnamon or Ceylon cinnamon for supplemen-
tation in view of its low coumarin content. However
there are no clinical trials that demonstrate its efficacy,
and should be addressed in future clinical trials.
Integrative medicine and cinnamon
Integrative medicine—an approach that combines con-
ventional and alternative therapies with an emphasis on
natural, less invasive evidence-based options—is well suited
to the management of complex chronic diseases like type 2
diabetes mellitus [16]. Published research in the field of this
new discipline is extremely sparse but many academic insti-
tutions offer information, counseling and clinical therapy
sessions [73, 74]. Previous work has shown that patients
often do not disclose the complementary medicines they
use to their physicians but practice these remedies on their
own [75–77]. The common reasons for non-disclosure
seem to be the passive or negative attitudes towards CAM
by conventional physicians and their failure to enquire from
patients regarding CAM use [75, 77]. However the focus in
integrative medicine would be to allow evidence-based
complementary practices alongside conventional therapy,
thus empowering the patient to be a contributor of the
management team. Conventional health care teams would
need to be knowledgeable as well as acknowledge these
evidence-based complementary practices. Cinnamon has
the potential to be practiced as an integrative medicine in
instances of mild diabetes where monotherapy is only re-
quired. Similarly it may have a place in instances of high
initial FPG values and high HbA1C. Further research on
the safety and efficacy of cinnamon as well as the feasibility
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of it as a component of integrative medicine needs to be
performed.
Conclusion
Both true cinnamon and cassia cinnamon has the poten-
tial to lower blood glucose in animal models and humans.
Short duration of studies and poor design has made the
available evidence difficult to interpret. Ceylon cinnamon
has not been studied in humans and its low coumarin
content particularly makes it an ideal supplement. Well-
designed trials with adequate power to interpret the end-
points are urgently required.
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